Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia.
Thirty-five patients newly diagnosed with chronic myeloid leukemia received pegylated interferon alpha-2b (PEG-IFN) alone or combined with intermittent Ara-C for a median of 6.5 months (range: 1.4-19.2). The median weekly PEG-IFN dose was 4.0 microg/kg. Complete hematologic, major and complete cytogenetic responses were observed in 73%, 32% and 14%, respectively. Extra-hematologic side-effects were frequent and 20% of patients had grade III-IV hematologic toxicity.
Cervantes
Francisco
F
Camós
Mireia
M
Boqué
Concha
C
Besses
Carles
C
Alcalá
Antonio
A
Sureda
Anna
A
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins
D000964:Antimetabolites, Antineoplastic; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003561:Cytarabine; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a